NASDAQ:NVAXNovavax Stock Price, Forecast & News

Novavax's stock was trading at $10.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVAX shares have increased by 1,083.8% and is now trading at $124.42.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Novavax.

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Novavax.

Novavax, Inc. (NASDAQ:NVAX) released its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the Zacks' consensus estimate of ($0.60) by $0.30. The biopharmaceutical company had revenue of $35.50 million for the quarter, compared to analysts' expectations of $5.67 million. The business's revenue for the quarter was up 944.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.69) EPS.
View Novavax's earnings history.

Shares of Novavax reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

7 equities research analysts have issued 12 month target prices for Novavax's stock. Their forecasts range from $15.00 to $275.00. On average, they anticipate Novavax's share price to reach $124.07 in the next twelve months. This suggests that the stock has a possible downside of 0.3%.
View analysts' price targets for Novavax.

Media headlines about NVAX stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novavax earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Novavax.

Novavax saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 7,360,000 shares, an increase of 28.9% from the April 30th total of 5,710,000 shares. Based on an average daily volume of 10,890,000 shares, the days-to-cover ratio is presently 0.7 days.
View Novavax's Short Interest.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Egalet (EGLT), Palo Alto Networks (PANW), NVIDIA (NVDA), EXACT Sciences (EXAS), Moderna (MRNA), Akebia Therapeutics (AKBA), Advanced Micro Devices (AMD) and Pfizer (PFE).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (0.51%), Goldman Sachs Group Inc. (0.34%), California Public Employees Retirement System (0.22%), Swiss National Bank (0.20%), State of Wisconsin Investment Board (0.16%) and Creative Planning (0.16%). Company insiders that own Novavax stock include Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Rachel K King.
View institutional ownership trends for Novavax.

NVAX stock was sold by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Goldman Sachs Group Inc., Beirne Wealth Consulting Services LLC, UBS Group AG, Leap Investments LP, Commonwealth Equity Services LLC, and Sargent Investment Group LLC. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino, and Michael A Mcmanus Jr.
View insider buying and selling activity for Novavax.

NVAX stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Swiss National Bank, California Public Employees Retirement System, Virtu Financial LLC, Federated Hermes Inc., State of Wisconsin Investment Board, Barclays PLC, and EAM Investors LLC. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax.

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVAX stock can currently be purchased for approximately $124.42.

Novavax has a market capitalization of $7.62 billion and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe.

The official website for Novavax is www.novavax.com.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]